LL-37

Name: LL-37
Brand: PeptideValidation.com
Availability: OutOfStock

LL-37 Recovery, Healing & Tissue Repair Peptides

LL-37 is a groundbreaking, naturally occurring human antimicrobial peptide (AMP) designed to support advanced immune function, profound wound healing, and robust tissue recovery. By uniquely targeting both complex pathogens and the body's intrinsic repair mechanisms simultaneously, it offers unparalleled efficacy in eradicating biofilms, neutralizing chronic inflammation, and accelerating complete physiological healing when administered under medical supervision.

Access Certified Vendors View Testing Standards

View full details

Quick Facts

LL-37 is a groundbreaking, naturally occurring human antimicrobial peptide (AMP) designed to supportadvanced immune function, profound wound healing, and robust tissue recovery. By uniquely targetingboth complex pathogens and the body's intrinsic repair mechanisms simultaneously, it offersunparalleled efficacy in eradicating biofilms, neutralizing chronic inflammation, and acceleratingcomplete physiological healing when administered under medical supervision.

Generic Name

LL-37 (Cathelicidin Antimicrobial Peptide)

Drug Class

Drug Class Antimicrobial and Immunomodulatory Peptide

Adminstration

Subcutaneous Injection or Topical Application

FDA Approval

Investigational / Compounded (Requires Medical Necessity)

Typical MaintenanceDose

100mcg to 250mcg

Starting Dose

100mcg

Injection Sites

Injection Sites Abdomen, Thigh, near localized injury (subcutaneous)

Treatment Duration

Short-term cycles (4-6 weeks) under medical supervision

Storage

Refrigerated (2°C - 8°C) once reconstituted

Prescription Required

Yes

Average Outcome

Significant reduction in inflammatory markers and accelerated tissueclosure

Best For

Advanced wound healing, biofilm disruption, and autoimmune support

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational peptide that belongs to a class of compounds known as triple receptor agonists. It is designed to activate three key metabolic hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.Retatrutide is being studied in metabolic and obesity-related research because of its unique multi-receptor mechanism of action. Unlike traditional single-pathway compounds, Retatrutide targets multiple metabolic signaling pathways that researchers believe may influence appetite regulation, energy expenditure, glucose metabolism, and body weight.Developed by Eli Lilly and Company, Retatrutide has become one of the most widely discussed investigational peptides in metabolic research and is currently being evaluated in ongoing clinical studies. Retatrutide is a novel triple agonist peptide targeting the GLP-1, GIP, and glucagon receptors simultaneously.

Retatrutide (LY3437943) is a novel investigational peptide developed by Eli Lilly and Company. It is classified as a triple agonist, meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-receptor engagement sets Retatrutide apart from every other metabolic research peptide currently in development or on the market.

As of 2023, Retatrutide has demonstrated unprecedented weight loss outcomes in Phase 2 clinical trials, with participants achieving a mean body weight reduction of up to 24.2% over 48 weeks — making it the most effective weight loss compound ever tested in a randomized controlled trial at the time of publication.

How Does Retatrutide Work?

Retatrutide works by binding to and activating three key metabolic hormone receptors in the body. Each receptor plays a distinct role in energy metabolism, appetite regulation, and glucose homeostasis. By engaging all three simultaneously, Retatrutide creates a synergistic effect that exceeds what any single or dual agonist can achieve.

Why Was Retatrutide Developed?

Retatrutide was developed to address the limitations of first and second generation metabolic peptides. While semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) demonstrated significant efficacy, researchers hypothesized that adding glucagon receptor activity could further enhance energy expenditure through thermogenesis and hepatic fat reduction.

What Receptors Does It Target?

GLP-1 Receptor — Controls insulin secretion, slows gastric emptying, and signals satiety to the brain
GIP Receptor — Enhances insulin sensitivity, augments GLP-1 effects, and modulates lipid metabolism
Glucagon Receptor — Increases energy expenditure via thermogenesis and reduces hepatic fat accumulation

How Is Retatrutide Different From Other Peptides?

Only peptide in development targeting GLP-1, GIP AND glucagon simultaneously
Highest weight loss outcomes ever recorded in a randomized controlled trial (24.2%)
Significant reduction in liver fat — addressing NAFLD and metabolic liver disease
Improvements in cardiometabolic markers including blood pressure and lipid profiles
Once-weekly subcutaneous injection with a favorable tolerability profile

💉 Receptor Target

GLP-1 Receptor

Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and activates satiety pathways in the hypothalamus to reduce food intake.

⚡ Receptor Target

GIP Receptor

Enhances glucose-stimulated insulin secretion, improves insulin sensitivity in peripheral tissues, augments GLP-1 activity, and modulates lipid metabolism and adipose tissue function.

🔥 Receptor Target

Glucagon Receptor

Increases hepatic glucose production, stimulates thermogenesis and energy expenditure, promotes lipolysis, and directly reduces liver fat — a key differentiator from GLP-1/GIP dual agonists.

The simultaneous activation of all three receptors creates a synergistic metabolic effect that exceeds single-receptor targeting alone.

LL-37 Research Studies

Published clinical and preclinical research on LL-37.

Biofilm Disruption Trials2023

LL-37 Biofilm Disruption Trials

Extensive in-vitro and in-vivo studies demonstrate LL-37's capacity to significantly reduce the mass of established Pseudomonas aeruginosa and Staphylococcus aureus biofilms, lowering the minimum inhibitory concentration (MIC) required for traditional antibiotics when used in tandem.

Venous Leg Ulcer Healing

LL-37 Venous Leg Ulcer Healing

Clinical trials investigating the topical application of LL-37 on hard-to-heal venous leg ulcers showed a marked increase in the rate of re-epithelialization and a statistically significant reduction in wound area compared to standard care placebos over a 4-week period.

Immunomodulatory Benefits

LL-37 Immunomodulatory Benefits

Research consistently highlights rapid and sustained improvements in regulating systemic inflammatory responses, heavily reducing circulating levels of pro-inflammatory cytokines while increasing anti-inflammatory signaling pathways.

Retatrutide vs Other Peptides

How does Retatrutide compare to other leading research peptides?

Feature	Semaglutide	Tirzepatide	Liraglutide
Weekly Injection	Yes	Yes	Daily
Appetite Control	Excellent	Excellent	Moderate
Average Weight Loss	15-17%	20%+	6-8%
Dosing Frequency	Weekly	Weekly	Daily
Blood Sugar Support	Yes	Yes	Yes
Long-Term Data	Extensive	Growing	Established
Convenience	High	High	Moderate

Tirzepatide vs Semaglutide

Tirzepatide may produce greater weight loss due to its dual-agonist mechanism (GIP + GLP-1).
Semaglutide currently has longer-term weight management data available.
Both medications require physician supervision and dose titration.

Tirzepatide vs Liraglutide

Tirzepatide requires only weekly injections, whereas Liraglutide requires daily administration.
Tirzepatide produces vastly superior weight reduction (20%+ compared to Liraglutide's 6-8%).

PeptideValidation Testing & Validation

Every product undergoes rigorous multi-layer laboratory validation.

🔬

Medical History

History of autoimmune diseases or hypersensitivity to peptide therapies.
Current status of active infections, particularly bacterial or fungal.
Comprehensive review of ongoing antibiotic or immunosuppressive treatments.
Gastrointestinal history, specifically inflammatory bowel disease markers.

🔬

Laboratory Testing

Comprehensive Metabolic Panel (CMP) and Complete Blood Count (CBC).
Inflammatory markers: C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR).
Specific infectious disease panels (if indicated, e.g., Lyme titers).
Immune function panels (WBC differentials).

🔬

Monitoring During Treatment

MDT

Trajectory of wound closure and skin integrity.
Reduction in localized pain, erythema (redness), and swelling.
Gastrointestinal symptom improvements (bloating, digestion, comfort).
Overall tolerability and systemic energy levels.
Patients are typically reviewed bi-weekly during active administration cycles to ensure optimal healing and safety.

Frequently Asked Questions

Everything you need to know about peptide testing, certification, and compliance.

How quickly does LL-37 work?

Many patients begin to notice a significant reduction in localized inflammation and pain within the first
48 to 72 hours of starting treatment. Measurable changes in wound dimensions or systemic
inflammatory symptoms typically become apparent within the first two weeks of sustained therapy.

Can LL-37 replace my antibiotics?

No. While LL-37 has potent antimicrobial properties, it is usually utilized as an adjunctive therapy
alongside targeted antibiotics or to eradicate biofilms that antibiotics cannot penetrate. Any changes to
prescribed antibiotic regimens must be strictly coordinated by a healthcare provider.

Is LL-37 taken continuously?

Unlike long-term metabolic medications, LL-37 is generally administered in specific, short-term cycles
(e.g., 4 to 6 weeks) tailored to a specific healing goal or acute infection clearance, followed by an
evaluation period.

Does LL-37 require refrigeration?

Yes. Once the lyophilized powder is reconstituted with bacteriostatic water, the vial must be stored in
the refrigerator between 2°C and 8°C to maintain stability and prevent degradation of the peptide
sequence.

Can I combine LL-37 with other peptides?

Yes. LL-37 is frequently and safely combined with tissue-repairing peptides like BPC-157 and TB-500.
This combination creates a synergistic effect, where LL-37 cleanses the infectious/inflammatory
environment, allowing BPC-157 and TB-500 to maximize structural repair.

Certification Standards

Certified Vendor Requirements

To qualify as a PeptideValidation.com Certified Vendor, companies must meet our rigorous multi-step testing and documentation standards. Certification is not bought — it is earned through independent verification.

🏆 Apply for Certification

To qualify, vendors must:

📦

Submit Batch Testing
Vendors must submit product samples for independent third-party lab testing before listing.
✅

Pass Purity Requirements
All products must meet minimum purity thresholds verified by HPLC analysis.
🔬

Verify Identity via LC-MS
Molecular identity of each compound confirmed through liquid chromatography-mass spectrometry.
📄

Maintain Full Documentation
COAs, batch records, and testing documentation must be publicly available on the vendor profile.
🔄

Undergo Quarterly Re-Testing
Certification requires mandatory re-testing every quarter to maintain active certified status.